Table 1.
Demographic and clinical characteristics in IV edaravone-treated and non-IV edaravone-treated patients with ALS after matching.
| IV edaravone-treated cases | Non-IV edaravone-treated controls | Difference | Difference 95% CI | |
|---|---|---|---|---|
| N | 318 | 318 | ||
| Age, mean (SD) | 62.9 (10.1) | 62.7 (10.2) | –0.1981 | –1.7815, 1.3853 |
| Sex, no. (%) | ||||
| Female | 134 (42.1) | 134 (42.1) | 0 | –0.0543, 0.0543 |
| Male | 184 (57.9) | 184 (57.9) | ||
| Medicare Advantage, no. (%) | 189 (59.4) | 189 (59.4) | 0 | –0.0540, 0.0540 |
| Race, no. (%) | ||||
| White | 226 (71.1) | 236 (74.2) | –0.0314 | –0.0804, 0.0175 |
| Black | 28 (8.8) | 18 (5.7) | 0.0314 | –0.0030, 0.0599 |
| Other | 35 (11.0) | 33 (10.4) | 0.0063 | –0.0277, 0.0403 |
| Unknown | 29 (9.1) | 31 (9.7) | –0.0063 | –0.0384, 0.0258 |
| Region, no. (%) | ||||
| Midwest | 64 (20.1) | 86 (27.0) | –0.0692 | –0.1157, 0.0227 |
| Northeast | 51 (16.0) | 59 (18.6) | –0.0252 | –0.0667, 0.0164 |
| South | 131 (41.2) | 101 (31.8) | 0.0943 | –0.0417, 0.1470 |
| West | 72 (22.6) | 71 (22.3) | 0.0031 | –0.0427, 0.0490 |
| Unknown | 0 (0.0) | 1 (0.3) | –0.0031 | –0.0075, 0.0012 |
| Pre-index disease duration (days), mean (SD) | 211.8 (187.6) | 203.7 (285.5) | –8.0440 | –45.6752, 29.5871 |
| Riluzole prescription, no. (%) | 208 (65.4) | 208 (65.4) | 0 | –0.0523, 0.0523 |
| Pre-index cardiovascular disease, no. (%) | 29 (9.1) | 29 (9.1) | 0 | –0.0316, 0.0316 |
| Pre-index gastrostomy tube, no. (%) | 24 (7.5) | 24 (7.5) | 0 | –0.0290, 0.0290 |
| Pre-index artificial nutrition, no. (%) | 43 (13.5) | 38 (11.9) | 0.0157 | –0.0209, 0.0524 |
| Pre-index noninvasive ventilation, no. (%) | 48 (15.1) | 54 (17.0) | –0.0189 | –0.0592, 0.0215 |
| Pre-index hospitalisation, no. (%) | 73 (23.0) | 73 (23.0) | 0 | –0.0462, 0.0462 |
ALS, amyotrophic lateral sclerosis. IV, intravenous.